Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | GNPAT | O15228 | 2/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 4/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632045 | 0.92 | MAGI3 (0.39) | PTPN1GNPATMMEKEAP1F2 | |
| SCHEMBL11134385 | 0.88 | GNPAT (0.47) | PTPN1GNPATEDNRAMMECASP3 | |
| SCHEMBL30997434 | 0.88 | MME (0.38) | MMEOPRM1OPRD1 | |
| SCHEMBL29530913 | 0.85 | MME (0.40) | MMEMAGI3OPRM1OPRD1 | |
| SCHEMBL31453800 | 0.84 | OPRM1 (0.40) | MMEOPRM1OPRD1 | |
| SCHEMBL30632039 | 0.83 | IL23R (0.40) | MMEKEAP1MAGI3 | |
| SCHEMBL30390358 | 0.82 | CD274 (0.41) | MMEOPRM1OPRD1 | |
| SCHEMBL30254475 | 0.82 | OPRM1 (0.39) | MMEMAGI3OPRM1OPRD1 | |
| SCHEMBL30788325 | 0.82 | BACE1 (0.38) | CASP3CASP7 | |
| SCHEMBL31094977 | 0.81 | PTPN1 (0.46) | PTPN1GNPATEDNRAKEAP1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | AVELAS ACQUISITION CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | PTPN1 2828/4885GNPAT 1008/4885EDNRA 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.